Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Alpelisib and fulvestrant for advanced breast cancer: SOLAR-1

ESMO 2018

19 - 23 Oct 2018

Published: 20 Oct 2018

Views: 3760

Rating:

Save

Prof Fabrice André - Institut Gustave Roussy, Paris, France

Prof Fabrice André presents data at the ESMO 2018 congress in Munich from a phase III combination therapy trial including a targeted PI3K inhibitor to treat men and post-menopausal women with advanced breast cancer.

For more on these findings, watch his interview with ecancer here.

Related Videos

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof...

ESMO 2024: Optimising the personalisation of prostate cancer treatment ( Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg )

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA

Saruparib shows encouraging efficacy and safety in mutant advanced solid tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Housten, USA )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Preoperative endocrine therapy in premenopausal women leads to sparing...

Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany

Preoperative endocrine therapy in premenopausal women leads to sparing chemotherapy in additional patients ( Dr Oleg Gluz - Krankenhaus Bethesda, Mönchengladbach, Germany )

A biomarker led approach to bladder cancer

Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr...

A biomarker led approach to bladder cancer ( Prof Andrea Necchi, Dr Guillermo De Velasco, Prof Arlene Siefker-Radtke and Dr Yohann Loriot )

Gynaecological cancer: New targets and immunotherapy developments

Dr Mark Shahin - Jefferson Health, Philadelphia, USA

Gynaecological cancer: New targets and immunotherapy developments ( Dr Mark Shahin - Jefferson Health, Philadelphia, USA )

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic...

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City...

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )

The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer

Dr Delia Guaqueta - Memorial Healthcare System, Miami, USA

The role of CDK4/6 inhibitors in the treatment of metastatic breast cancer ( Dr Delia Guaqueta - Memorial Healthcare System, Miami, USA )

More from ecancer